ProCE Banner Activity

STAMPEDE Combined Analysis of ADT Plus Abiraterone Acetate + Prednisolone ± Enzalutamide vs ADT Alone in High-Risk Nonmetastatic Prostate Cancer

Slideset Download
Conference Coverage
In this combined analysis from the ongoing STAMPEDE platform trial, 2 years of abiraterone acetate plus prednisolone added to ADT was associated with a significant improvement in metastasis-free survival and OS in patients with high-risk nonmetastatic prostate cancer.

Released: September 30, 2021

Expiration: September 29, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc